"We have urgent patient needs right now. Every day that goes by, the clock is ticking for people with chronic illness and the federal government isn't designed to respond to that kind of urgency," she said.
Kevin Eggan, chief scientific officer for the New York Stem Cell Foundation, and an assistant professor of stem cell and regenerative biology at Harvard University, agreed with Solomon, adding, "Federal money isn't responsive to immediate needs and short timelines. Sometimes, with small, strategic infusions of money, there can be a massively changing shift in research."
For a primer on stem cells, visit the U.S. National Institutes of Health.
SOURCES: Story Landis, Ph.D., director, National Institute of Neurological Diseases and Stroke, and head, NIH Stem Cell Task Force, Bethesda, Md.; Alan J. Lewis, Ph.D., president and CEO, Juvenile Diabetes Research Foundation International, New York City; Susan Solomon, chief executive officer, New York Stem Cell Foundation, New York City; Kevin Eggan, Ph.D., assistant professor, stem cell and regenerative biology, Harvard University, Boston, and chief scientific officer, New York Stem Cell Foundation, New York City; Meri Firpo, Ph.D., assistant professor, The Stem Cell Institute, University of Minnesota, Minneapolis; NIH Guidelines for Human Stem Cell Research, July 6, 2009
All rights reserved